Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT

Ian Roberts,1* Haleema Shakur-Still,1 Amy Aeron-Thomas,2 Danielle Beaumont,1 Antonio Belli,3 Amy Brenner,1 Madeleine Cargill,1 Rizwana Chaudhri,4 Nicolas Douglas,5 Lauren Frimley,1 Catherine Gilliam,1 Amber Geer,1 Zahra Jamal,1 Rashid Jooma,6 Raoul Mansukhani,1 Alec Miners,5 Jason Pott,7 Danielle Prowse,1 Temitayo Shokunbi8 and Jack Williams5

1Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK
2RoadPeace, London, UK
3National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital, Birmingham, UK
4Department of Obstetrics and Gynaecology, Rawalpindi Medical University, Rawalpinidi, Pakistan
5Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK
6Department of Surgery, The Aga Khan University Medical College, Karachi, Pakistan
7Emergency Department, Barts Health NHS Trust, The Royal London Hospital, London, UK
8Department of Anatomy and Surgery, University of Ibadan, Ibadan, Nigeria

*Corresponding author Ian.Roberts@lshtm.ac.uk

Declared competing interests of authors: Ian Roberts reports grants from the National Institute for Health Research (NIHR) Health Technology Assessment programme, the JP Moulton Charitable Trust, the Department of Health and Social Care, the Department for International Development, the Global Challenges Research Fund, the Medical Research Council and the Wellcome Trust (Joint Global Health Trials scheme) during the conduct of the study. Ian Roberts and Haleema Shakur-Still report membership of Clinical Trial Units (CTUs) funded by the NIHR CTU Management Committee.

Published April 2021
DOI: 10.3310/hta25260
Scientific summary

The CRASH-3 international RCT
Health Technology Assessment 2021; Vol. 25: No. 26
DOI: 10.3310/hta25260

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Traumatic brain injury is the leading cause of injury-related death and disability globally. Each year, worldwide, there are over 60 million new cases of traumatic brain injury. Tranexamic acid reduces deaths due to blood loss in trauma patients with significant extracranial bleeding. Intracranial bleeding is common after traumatic brain injury and can cause brain herniation and death. Tranexamic acid may improve outcomes in patients with intracranial bleeding by reducing the expansion of intracranial haemorrhages. This is supported by data from a meta-analysis of randomised controlled trials of tranexamic acid in traumatic brain injury, which showed a significant reduction in haemorrhage growth and mortality with tranexamic acid. An effective, widely practicable and affordable treatment for traumatic brain injury could save many thousands of lives and substantially reduce the burden of disability.

Objective

We assessed the effects and cost-effectiveness of tranexamic acid in traumatic brain injury patients on death, disability, vascular occlusive events, seizures, complications and adverse events.

Methods

The CRASH-3 (Clinical Randomisation of an Antifibrinolytic in Significant Head Injury-3) trial was an international, multicentre, randomised, placebo-controlled trial conducted in 175 hospitals in 29 countries. Adults with traumatic brain injury (n = 12,737) who were within 3 hours of injury and had a Glasgow Coma Scale score of ≤ 12 or any intracranial bleeding on computerised tomography scan, and no significant extracranial bleeding, were eligible. The time window for eligibility was originally within 8 hours of injury. However, in September 2016, in response to evidence external to the trial indicating that tranexamic acid is unlikely to be effective when initiated beyond 3 hours of injury, the Trial Steering Committee amended the protocol to limit recruitment to within 3 hours of injury.

Patients were randomly allocated to receive tranexamic acid (loading dose of 1 g over 10 minutes and then infusion of 1 g over 8 hours) or matched placebo. Patients were assigned to their treatment group by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers and those assessing outcomes were masked to allocation.

The primary outcome was head injury death in hospital within 28 days of injury in patients randomised within 3 hours of injury. Secondary outcomes were early head injury death (within 24 and 48 hours after injury), all-cause and cause-specific mortality, disability, vascular occlusive events (myocardial infarction, stroke, deep-vein thrombosis, pulmonary embolism), seizures, complications, neurosurgery, days in an intensive care unit and adverse events within 28 days of randomisation. A diagnosis of deep-vein thrombosis or pulmonary embolism was recorded only if there was a positive result on imaging (e.g. ultrasound) or at post-mortem examination. We assessed the cost-effectiveness of tranexamic acid versus no treatment from a UK NHS perspective using a Markov model and data directly from the CRASH-3 trial. We estimated incremental cost-effectiveness ratios by dividing the incremental costs (in Great British pounds) by the incremental quality-adjusted life-years. We compared incremental cost-effectiveness ratios to the UK cost-effectiveness threshold of £20,000 per quality-adjusted life-year.
To minimise the risk of missing data, we developed simple data collection tools and kept data collection to a minimum. For the primary analysis, we conducted a complete-case analysis with no imputation for missing data. All analyses were by intention to treat. A subgroup analysis was conducted of the effect of tranexamic acid according to the time interval between injury and tranexamic acid treatment (\( \leq 1 \), > 1 to \( \leq 3 \), > 3 hours). The effects of tranexamic acid on the primary outcome were also stratified by severity of head injury, blood pressure and age.

**Results**

Patients were allocated to tranexamic acid (\( n = 6406 \)) or to placebo (\( n = 6331 \)); 6359 and 6280 patients, respectively, were analysed. A total of 9202 patients were enrolled within 3 hours of injury, of whom 9127 had outcome data available for analysis (tranexamic acid group, \( n = 4613 \); placebo group, \( n = 4514 \)).

**Primary outcome**

Among patients treated early, the risk of head injury death was 18.5% in the tranexamic acid group versus 19.8% in the placebo group (855 vs. 892 events, risk ratio 0.94, 95% confidence interval 0.86 to 1.02). In the prespecified sensitivity analysis that excluded patients with a Glasgow Coma Scale score of 3 or with bilateral unreactive pupils at baseline (tranexamic acid group, \( n = 3880 \); placebo group, \( n = 3757 \)), the risk of head injury death was 12.5% in the tranexamic acid group and 14.0% in the placebo group (485 vs. 525 events; risk ratio 0.89, 95% confidence interval 0.80 to 1.00). There was a reduction in the risk of head injury death with tranexamic acid in those with mild to moderate head injury [5.8% (166/2846) vs. 7.5% (207/2769); risk ratio 0.78, 95% confidence interval 0.64 to 0.95], but in those with severe head injury [39.6% (689/1739) vs. 40.1% (685/1710); risk ratio 0.99, 95% confidence interval 0.91 to 1.07] there was no clear evidence of a reduction (\( p \)-value for heterogeneity = 0.030). Early treatment was more effective in mild and moderate head injury (\( p = 0.005 \)), but there was no obvious impact of time to treatment in severe head injury (\( p = 0.73 \)).

**Secondary outcome**

The risk of disability, vascular occlusive events and seizures was similar in both groups. There was no apparent benefit or harm among those randomised beyond 3 hours of injury.

The cost-effectiveness analysis showed that tranexamic acid is highly cost-effective for mild and moderate traumatic brain injury with an incremental cost-effectiveness ratio of £4288 per quality-adjusted life-year gained, and was also cost-effective for patients with both pupils reactive, with an incremental cost-effectiveness ratio of £6097 per quality-adjusted life-year gained. The results were highly robust in probabilistic sensitivity analyses, with treatment 99% likely to be cost-effective at the UK cost-effectiveness threshold of £20,000 per quality-adjusted life-year, in both of these populations.

**Conclusion**

Tranexamic acid is safe in traumatic brain injury patients, and treatment within 3 hours of injury reduces head injury deaths. Patients should be treated as soon as possible after injury. Treatment is highly likely to be cost-effective for those with mild or moderate traumatic brain injury, or those with both pupils reactive.
Implications for practice

On the basis of the CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage-2) trial results, tranexamic acid was included in guidelines for the pre-hospital care of patients with trauma. However, patients with isolated traumatic brain injury were specifically excluded. The CRASH-3 trial provides evidence that tranexamic acid is safe for use in patients with traumatic brain injury and that treatment within 3 hours of injury reduces head injury-related deaths. In the light of this evidence, the exclusion of patients with isolated traumatic brain injury from tranexamic acid treatment guidelines seems unnecessary. This is supported by economic evidence that shows that the treatment of patients with mild or moderate traumatic brain injury, or with both pupils reactive, is highly cost-effective.

Recommendations for future research

Based on the CRASH-3 trial results, patients with traumatic brain injury within 3 hours of injury, who have a Glasgow Coma Scale score of ≤ 12 or any intracranial bleeding on computerised tomography scan are likely to be treated with tranexamic acid, either at the scene of the injury or after arrival in hospital. However, most patients with mild traumatic brain injury will not receive pre-hospital tranexamic acid and, by the time they have been assessed in hospital, for many patients it will be either too late to give tranexamic acid or too late to experience the full benefits of early treatment. Even mild traumatic brain injury can have important consequences (death and disability), especially in older adults. Further research into the effects of the early (including pre-hospital) use of tranexamic acid in older adults with mild traumatic brain injury is needed.

Immediate tranexamic acid treatment improves survival, but the treatment benefit decreases by about 10% for every 15 minutes of treatment delay until 3 hours, after which there is no benefit. One of the main obstacles to further reducing treatment delay is the need for an intravenous injection. If tranexamic acid could be given by intramuscular injection, this might reduce the time to tranexamic acid treatment. To determine whether or not intramuscular tranexamic acid has the potential to improve the care of trauma patients, research is required to understand the pharmacokinetics of tranexamic acid following intramuscular use. If we find that intramuscular tranexamic acid is well absorbed, with therapeutic tranexamic acid levels achieved in a timely manner, intramuscular tranexamic acid would provide a rapid alternative to intravenous injection use when immediate intravenous injection administration is not possible.

Trial registration

This trial is registered as ISRCTN15088122 (19 July 2011), ClinicalTrials.gov number NCT01402882 (26 July 2011) and EudraCT 2011-003669-14 (12 June 2012) and in the Pan African Clinical Trial Registry as PACTR20121000441277 (30 October 2012).

Funding

The project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 26. See the NIHR Journals Library website for further project information. In addition funding was provided by JP Moulton Charitable Trust, Joint Global Health Trials (Medical Research Council, Department for International Development and the Wellcome Trust). This project was funded by the NIHR Global Health Trials programme.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)

Impact factor: 3.370

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 14/190/01. The contractual start date was in October 2014. The draft report began editorial review in February 2020 and was accepted for publication in July 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

Copyright © 2021 Roberts et al. This work was produced by Roberts et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.

For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk